One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Agenus logo
Agenus AGEN
$ 7.02 -2.36%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Agenus Financial Ratios 2025-2008 | AGEN

Brief overview of Agenus's multiples and efficiency

Ratios are assessed across five available annual reports in the 2021–2025 interval.

The latest available valuation ratios are EV/EBITDA 0.45x (median 0.87x), P/S 0.86x (median 0.26x), P/B 0.43x (median 0.06x). On average, this basket is 225.7% above its own five-year medians. The market is pricing in elevated future expectations.

Capital efficiency is characterized by ROE 1.1%, ROA -1.4%, ROCE 7.4%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.

PEG is 0.4x. Price is low relative to embedded growth, though the ratio depends heavily on forecast quality.

Conclusion

Agenus's valuation is above historical references while efficiency remains restrained, increasing sensitivity to weak reports.

Annual Financial Ratios Agenus

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
-31.7 -0.3 -0.0 -0.1 -0.0 -0.0 -4.8 -2.4 -3.0 -2.5 -2.8 -7.1 -3.1 -9.1 -2.4 - - -

P/S

0.9 0.7 0.1 0.3 0.0 0.0 3.4 10.5 8.4 14.2 9.9 43.1 30.8 6.5 20.3 - - -

EPS

- -10.6 -13.8 -15.6 -0.1 -1.1 -0.8 -1.4 -1.2 -1.5 -1.1 -0.7 -1.1 -0.5 -1.2 -1.4 -2.4 -

EV (Enterprise Value)

94.8 M 30.2 M -65.4 M -153 M -291 M -99.2 M 838 M 643 M 513 M 446 M 281 M 326 M 106 M 128 M 85.8 M -19.8 M -20.1 M -24.5 M

EBITDA per Share

-0.34 -4.99 -8.16 -12.2 142 -638 -0.427 -1.07 -1.03 -1.16 -0.765 -0.586 -0.82 -0.217 -0.846 - - -

EV/EBITDA

-9.3 -0.3 0.4 0.9 -9.0 0.9 -8.1 -2.9 -4.6 -3.8 -3.7 -8.0 -3.1 -23.0 -4.6 1.1 0.9 -

PEG

0.4 -0.0 -0.0 -0.0 -0.0 -0.0 -0.11 0.14 -0.19 0.09 0.05 -0.19 0.03 -0.16 -0.2 - - -

P/B

0.4 0.3 0.0 0.1 0.0 0.0 -2.2 -2.2 -4.7 -8.2 3.5 13.1 -20.9 -5.9 -2.7 - - -

P/CF

-1.3 -0.4 -0.0 -0.1 0.1 -0.0 -22.0 -2.9 -3.7 -3.5 -4.9 -7.3 -4.6 113.3 -3.4 - - -

ROE %

1.14 71.17 160.57 376.41 -83.40 18.52 46.54 91.49 159.19 324.58 -124.25 -184.57 671.16 64.34 111.74 148.95 178.60 -

ROA %

-1.36 -102.65 -82.01 -55.77 -6.16 -17.59 -69.31 -117.08 -87.20 -80.90 -36.28 -57.01 -86.33 -38.93 -117.51 -70.88 - -

ROCE %

7.44 36.91 99.51 292.81 74.76 57.56 -194.20 -183.14 -130.53 -90.86 -34.69 -56.08 -101.80 -27.76 -126.79 147.90 163.06 -

Current Ratio

- - - - - - 0.7 1.1 1.3 2.2 6.4 4.6 2.7 4.7 2.5 - - -

DSO

3.6 2.1 4.1 7.9 1.7 36.1 39.6 9.3 9.7 183.6 144.1 - 0.1 12.6 - 1.9 - -

DIO

- - - - - - - 0.2 0.2 0.3 0.5 1.6 - 0.5 - - - -

DPO

25795.9 46156.7 6006.2 1233.4 2498.3 2375.8 29.4 39.9 25.4 20.9 23.3 27.9 22.5 20.6 - - - -

Operating Cycle

- - - - - - 39.6 9.5 9.9 183.9 144.6 1.6 0.1 13.2 - 1.9 - -

Cash Conversion Cycle

- - - - - - 10.2 -30.4 -15.5 163.0 121.3 -26.4 -22.4 -7.5 - 1.9 - -

All numbers in USD currency

Quarterly Financial Ratios Agenus

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

0.02 -0.01 1.03 -0.37 2 -1 -1.03 -1.9399999999999995 -3.08 -2.52 -3.04 -2.3200000000000003 -3.29 -3.93 -4.31 -15.100000000000001 -0.19 -0.17 -0.19 -0.22999999999999998 0.76 -0.37 -0.27 -0.2 -0.28 -0.28 -0.31 -0.22 -0.33 -0.38 0.14 -0.4 -0.37 -0.24 -0.53 -0.35 -0.37 -0.32 -0.18 -0.3 -0.47 -0.33 -0.37 -0.18 -0.16 -0.53 -0.28 -0.41 -0.13 -0.13 -0.01 -0.16 -0.24 -0.4 -0.35 -0.23 -0.24 -0.31 0.29 -0.29 -0.28 -0.31 -0.33

EBITDA per Share

0.18 0.3 0.41 3.42 -0.05 -0.48 -0.41 -74.2 -1.31 -1.27 -1.45 -25.4 -2.3 -2.94 -3.27 -4.39 -139 -155 -131 0.26 804 -0.29 -198 0.13 -0.18 -0.18 -178 - -0.22 -0.28 215 - -0.19 -0.13 -392 - -0.27 -0.26 -0.13 - -0.37 -0.24 -0.31 - -0.11 -0.42 -0.27 - -0.11 - - - - - -0.18 - - - 0.37 - - - -0.24

ROE %

-14.97 -36.35 -28.30 -2.73 8.43 55.61 71.34 96.03 112.28 141.83 207.75 303.82 402.18 806.74 375.90 72.32 -194.12 -150.62 222.84 424.94 579.60 102.35 90.80 85.89 81.09 76.81 78.79 48.83 63.20 62.23 53.82 93.02 111.91 140.95 168.16 159.26 179.88 235.49 266.05 324.71 235.67 112.91 -16.61 -124.33 -215.27 -231.94 -209.74 -184.80 58.33 349.73 449.51 581.28 483.28 259.66 234.15 65.48 62.33 56.35 44.65 111.74 26.57 27.64 28.63

ROA %

16.63 43.31 28.52 -5.15 -20.76 -75.92 -78.97 -90.46 -84.94 -75.63 -75.47 -67.87 -70.31 -64.41 -56.59 -51.01 -47.87 5.56 -27.59 -39.50 -42.98 -108.81 -91.05 -89.29 -91.11 -95.86 -103.67 -71.34 -87.01 -81.94 -67.03 -118.04 -108.34 -110.23 -114.67 -87.24 -78.56 -77.92 -73.04 -80.93 -70.72 -50.16 -48.81 -36.30 -64.76 -70.23 -64.33 -57.08 -38.88 -47.56 -89.15 -105.42 -108.07 -108.20 -79.62 -39.61 -50.62 -58.87 -64.14 -117.51 -27.94 -29.07 -30.11

ROCE %

-27.83 -16.04 -5.40 5.53 19.17 29.14 37.84 50.99 45.37 73.97 131.52 216.56 318.93 630.59 232.60 2.03 -215.94 -40.30 312.44 461.58 584.62 73.99 62.75 55.34 61.01 62.41 36.05 22.57 37.69 31.36 37.30 48.93 90.70 113.68 121.56 97.35 189.94 208.51 241.89 224.40 208.76 69.24 -16.96 -88.44 -121.77 -143.05 -138.79 -112.93 26.06 296.26 375.64 521.19 408.00 203.91 117.14 14.27 35.59 32.36 23.68 68.00 21.32 22.57 24.11

DSO

46.1 28.1 11.3 3.2 1.9 1.9 1.4 1.0 1.7 2.3 42.9 14.6 4.5 5.0 8.3 18.6 55.7 44.2 4.9 52.5 4.2 15.3 13.0 3.8 55.5 30.1 52.6 43.1 74.6 94.6 9.8 13.3 6.7 5.4 57.8 12.4 30.8 24.6 21.1 185.8 233.0 157.1 162.0 117.1 130.6 140.2 118.5 26.1 27.0 13.7 29.4 0.3 12.6 11.5 22.8 46.2 58.0 80.4 1.9 - - - -

DPO

971.1 - - 1106.1 783.9 558.4 473.8 343.5 288.8 311.6 294.0 63.9 14055.5 17826.3 1744.4 54.7 11956.3 1703.0 5464.1 2879.6 2472.9 2643.2 1506.7 2131.3 2065.4 2714.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - - - - - - - - - - - - - - - - - - - - - - - 52.6 - 74.6 94.6 9.8 13.3 6.7 5.4 57.8 12.4 30.8 24.6 21.1 185.8 233.0 157.1 162.0 117.1 130.6 140.2 118.5 26.1 27.0 13.7 29.4 - 12.6 11.5 22.8 46.2 58.0 80.4 1.9 - - - -

Cash Conversion Cycle

- - - - - - - - - - - - - - - - - - - - - - - - - - 52.6 - 74.6 94.6 9.8 13.3 6.7 5.4 57.8 12.4 30.8 24.6 21.1 185.8 233.0 157.1 162.0 117.1 130.6 140.2 118.5 26.1 27.0 13.7 29.4 - 12.6 11.5 22.8 46.2 58.0 80.4 1.9 - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Agenus, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
- - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
- -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
- - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
- - $ 63.4 M usaUSA
Magenta Therapeutics Magenta Therapeutics
MGTA
- -7.74 % $ 41.6 M usaUSA
NovaBay Pharmaceuticals NovaBay Pharmaceuticals
NBY
- - $ 11.3 M usaUSA
NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals
NRBO
- 0.43 % $ 12 M usaUSA
OncoCyte Corporation OncoCyte Corporation
OCX
- 17.22 % $ 355 K usaUSA
Onconova Therapeutics Onconova Therapeutics
ONTX
- -0.47 % $ 21 M usaUSA
Opthea Limited Opthea Limited
OPT
- - $ 1.2 B australiaAustralia
Verastem Verastem
VSTM
$ 8.74 0.52 % $ 606 M usaUSA
BiomX BiomX
PHGE
$ 1.85 14.2 % $ 3.02 M israelIsrael
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
- -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
- - $ 301 M usaUSA
Pluristem Therapeutics Pluristem Therapeutics
PSTI
- -1.9 % $ 33.3 M israelIsrael
Qualigen Therapeutics Qualigen Therapeutics
QLGN
- 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
- - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
- -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
- - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
- - $ 2.64 M usaUSA
Sensei Biotherapeutics Sensei Biotherapeutics
SNSE
- - $ 17.5 M usaUSA
Sonnet BioTherapeutics Holdings Sonnet BioTherapeutics Holdings
SONN
- - $ 826 K usaUSA
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Synlogic Synlogic
SYBX
- - $ 7.07 M usaUSA
Virios Therapeutics, LLC Virios Therapeutics, LLC
VIRI
- 2710.01 % $ 72.9 M usaUSA
Vallon Pharmaceuticals Vallon Pharmaceuticals
VLON
- -6.47 % $ 5.76 M usaUSA
Vaxart Vaxart
VXRT
- -25.06 % $ 46.3 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
- - $ 485 M usaUSA
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 4.2 -0.71 % $ 651 M usaUSA
AbbVie AbbVie
ABBV
$ 293.87 0.19 % $ 520 B usaUSA